World

Former US Secretary of State Henry Kissinger passed away

Nov 30, 2023

Washington [US], November 30: Latest information, former US Secretary of State Henry Kissinger passed away on November 29 (US time), at the age of 100.
Former US Secretary of State Henry Kissinger passed away at his home in Connecticut on November 29 (morning of November 30 Vietnam time), at the age of 100, according to Reuters citing an announcement from consulting company Kissinger Associates Inc.
Kissinger served under two US presidents, leaving an indelible mark on US foreign policy, according to Reuters.
In the 1970s, Mr. Kissinger, as secretary of state under President Richard Nixon, participated in many events that marked major changes globally, leading to China's opening to diplomacy with the United States and negotiations. landmark arms control between the US and the Soviet Union.
Mr. Kissinger's importance as the leading architect of American foreign policy declined after Mr. Nixon resigned in 1974. However, Mr. Kissinger continued to be a diplomatic force under President Gerald Ford and held strong opinions for the rest of his life, according to Reuters.
Even at the age of 100, he remained active, attending meetings at the White House and publishing a book on leadership style. In July 2023, he made a surprise visit to Beijing to meet Chinese President Xi Jinping.
The statement from Kissinger Associates Inc did not mention the circumstances of his death. The consulting firm said Mr. Kissinger will be buried at a private family ceremony and then a public memorial service will be announced in New York City.
Source: ThanhNien Newspaper

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025